Unique ID issued by UMIN | UMIN000029481 |
---|---|
Receipt number | R000033664 |
Scientific Title | Multicenter research of comparison between prasugrel and clopidogrel in ischemic heart disease undergoing PCI |
Date of disclosure of the study information | 2017/10/10 |
Last modified on | 2020/10/16 11:11:53 |
Multicenter research of comparison between prasugrel and clopidogrel in ischemic heart disease undergoing PCI
comparison between prasugrel and clopidogrel
Multicenter research of comparison between prasugrel and clopidogrel in ischemic heart disease undergoing PCI
comparison between prasugrel and clopidogrel
Japan |
Ischemic heart disease
Cardiology |
Others
NO
Lower loading and maintenance doses of prasugrel have been established for Japanese patients (loading dose [LD]/maintenance dose [MD], 20/3.75mg) compared to those for Western patients (LD/MD, 60/10mg), considering the higher average age, lower body weight, and increased bleeding risk with other thrombotic agents in Japanese patients.
Although it has been reported that even low-dose prasugrel achieves stronger antiplatelet effect and fewer cardiovascular events compared to standard-dose clopidogrel in Japanese patients, there are limited data comparing the safety between low-dose prasugrel and standard-dose clopidogrel.
Safety,Efficacy
Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke.
Adverse events were defined as a composite of bleeding, hepatopathy, leukopenia, thrombopenia, exanthema, and MACE.
Observational
20 | years-old | <= |
100 | years-old | >= |
Male and Female
Ischemic heart disease patinets undergoing PCI between May 2014 to May 2016 who started newly prasugrel or clopidogrel and kept dual anti-platelet therapy.
Prescribed P2Y12 inhibitors before first PCI more than a month ago
Switching P2Y12 inhibitors within 2weeks without comprehensible reasons
Self-interruption of P2Y12 inhibitors
Follow-up periods within 2 weeks
Not documented doses of P2Y12 inhibitors
1500
1st name | Yoshio |
Middle name | |
Last name | Kobayashi |
Chiba University Graduate school of medicine
Cardiovascular medicine
260-0856
1-8-1, Inohana, Chuo ward, Chiba city, Chiba pref
043-222-7171
uiryosuke@msn.com
1st name | Satoshi |
Middle name | |
Last name | Tokimasa |
Chiba University Graduate school of medicine
Cardiovascular medicine
260-0856
1-8-1, Inohana, Chuo ward, Chiba city, Chiba pref
043-222-7171
YFD02270@nifty.com
Chiba University Graduate school of medicine
None
Self funding
Chiba University Graduate school of medicine
1-8-1, Inohana, Chuo ward, Chiba city, Chiba pref
043-222-7171
YFD02270@nifty.com
NO
2017 | Year | 10 | Month | 10 | Day |
Unpublished
Main results already published
2017 | Year | 10 | Month | 10 | Day |
2017 | Year | 10 | Month | 10 | Day |
2017 | Year | 10 | Month | 10 | Day |
2018 | Year | 10 | Month | 01 | Day |
none
2017 | Year | 10 | Month | 10 | Day |
2020 | Year | 10 | Month | 16 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033664
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |